DaVita (NYSE:DVA) Releases Quarterly Earnings Results, Beats Estimates By $0.43 EPS

DaVita (NYSE:DVA) released its quarterly earnings results on Thursday. The company reported $2.38 EPS for the quarter, topping the consensus estimate of $1.95 by $0.43, RTT News reports. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The business had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter in the previous year, the firm posted $1.58 earnings per share. The company’s revenue was up 6.9% compared to the same quarter last year. DaVita updated its FY24 guidance to $9.00-$9.80 EPS.

DaVita Stock Performance

DVA stock traded up $2.46 on Thursday, reaching $142.21. The company’s stock had a trading volume of 1,891,441 shares, compared to its average volume of 819,306. DaVita has a 52 week low of $71.51 and a 52 week high of $143.23. The company has a market capitalization of $12.47 billion, a P/E ratio of 18.89, a price-to-earnings-growth ratio of 1.24 and a beta of 1.04. The firm has a fifty day moving average of $133.13 and a two-hundred day moving average of $111.96. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael David Staffieri sold 29,488 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total value of $3,532,957.28. Following the completion of the sale, the chief operating officer now owns 37,687 shares of the company’s stock, valued at $4,515,279.47. The disclosure for this sale can be found here. Insiders sold 134,540 shares of company stock valued at $16,551,071 in the last three months. 1.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

DVA has been the topic of several research reports. UBS Group upped their price objective on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Barclays initiated coverage on DaVita in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective on the stock. Truist Financial upped their price objective on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. StockNews.com upgraded DaVita from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 25th. Finally, TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $118.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.